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Abstract
Background: Thiopurines are an effective treatment for moderate to severe inflammatory bowel 
disease [IBD] and can be used safely in pregnancy. Combining allopurinol with a lower dose 
of thiopurine can improve clinical efficacy and bypass some adverse reactions associated with 
thiopurine monotherapy. Data on allopurinol in pregnancy are scarce. We report on a total of 13 
cases where thiopurine and allopurinol co-therapy was used successfully to manage IBD during 
pregnancy without attributable adverse fetal effects.
Methods: Patients were retrospectively identified at our two hospitals, one in the UK and one in 
Australia, using local IBD databases. Data regarding pregnancy and fetal outcomes including in 
utero fetal ultrasound scans, APGAR scores, fetal birthweights and neonate checks were collected 
from patient notes.
Results: We identified 12 women with a total of 13 pregnancies treated with co-therapy before 
conception and for the duration of pregnancy. There were no miscarriages or spontaneous pre-term 
deliveries. There were 14 live births [seven vaginal deliveries; six caesarean sections]. Except for a 
primagravid twin pregnancy complicated by pre-eclampsia and twin-to-twin transfusion syndrome 
requiring caesarean section at 25 weeks, there were no low birthweight [< 2.5 kg] babies born and 
the APGAR scores of all babies were normal. No congenital malformations were identified.
Conclusions: Adverse pregnancy outcomes attributable to thiopurine and allopurinol co-therapy 
were not detected in our case series. Our study provides reassurance for clinicians and patients 
who wish to continue the thiopurine-allopurinol co-therapy combination before conception and 
during pregnancy to maintain remission of IBD.
Keywords:  Thiopurine; allopurinol; pregnancy
1. Introduction
Inflammatory bowel disease [IBD] affects many women of child-
bearing age. Thiopurines (azathioprine[AZA] and mercaptopurine 
[6MP]) are an effective oral treatment for moderate to severe IBD. 
There is considerable evidence to support their safety in pregnancy 
without adverse fetal effects1 such as low birthweight or congenital 
abnormalities.2 There is a strong medical consensus that advocates 
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the importance of maintaining disease remission before conception 
and during pregnancy3 because disease flares are the main predic-
tor of adverse pregnancy outcomes.4 The combination of allopuri-
nol with a lower dose of AZA or 6MP has been recently shown to 
circumvent some adverse drug reactions associated with thiopurines 
and improve efficacy of thiopurine monotherapy.5,6
Allopurinol is classed by regulatory bodies such as the 
Therapeutic Goods Association of Australia, or the US Food and 
Drug Administration [FDA], as a category C drug in pregnancy. 
However there are few data concerning allopurinol and pregnancy 
because few women of childbearing age require allopurinol therapy. 
Animal studies with allopurinol have demonstrated evidence of tera-
togenicity at high doses in mice7 but not in rats.8 There are only four 
reported cases of the combined use of thiopurine and allopurinol 
during pregnancy: one case report,9 where 6MP was used in con-
junction with allopurinol to successfully treat ulcerative colitis [UC], 
and a series of three cases of co-therapy from Australia.10 No adverse 
fetal outcomes were reported for any of the four pregnancies.
We report a total of 13 cases from two centres in the UK and one 
in Australia, where thiopurine and allopurinol co-therapy was used 
successfully to manage IBD from before conception and throughout 
the duration of pregnancy. This represents the largest case series of 
thiopurine and allopurinol co-therapy for IBD in pregnancy to date.
2. Case Report
Patients were retrospectively identified at East Surrey Hospital, UK, 
and the Mater Health Services’ Hospital in Brisbane, Australia, 
using our local electronic IBD databases. We identified patients 
from January 2010 to September 2013, treated with thiopurine and 
allopurinol, who became pregnant. All pregnancies of co-therapy 
patients were included. All female patients before commencing co-
therapy treatment were counselled about possible adverse reactions 
of medication and risks in pregnancy. Those considering pregnancy 
had additional consultations before conception to further discuss 
risks and benefits. Thiopurine S-methyltransferase [TPMT] activity 
and pre-pregnancy weight were used to calculate thiopurine dosing, 
which was reduced to one-third following addition of allopurinol as 
per Ansari et al.11
Patients were followed during their pregnancies in outpatient gas-
troenterology and obstetric clinics. IBD clinical activity was measured 
using clinical parameters—the simple clinical colitis score for UC and 
the Harvey Bradshaw Index for Crohn’s disease [CD] activity—at 
clinic visits. In addition we performed routine blood tests including 
haematology, biochemistry, liver function, and CRP. Fetal ultrasound 
scans were performed at 12, 22, and 28 weeks for all patients in the 
UK centre, and according to routine clinical practice in Australia. At 
birth, APGAR scores were calculated at 1 and 5 min, birthweights 
were measured and neonate checks were performed by a paediatri-
cian as routine practice for medically complex cases. Data regarding 
pregnancy and fetal/neonatal outcomes were collected retrospectively 
from patient notes. Postnatally women were contacted to ask about 
any neonatal complications including vaccination status.
We identified 12 females [9 UC, 3 CD] on co-therapy who 
became pregnant, with a total of 13 pregnancies during the study 
period [Table1]. All patients had been receiving thiopurine-allopuri-
nol co-treatment as part of their ongoing disease management and 
then continued treatment through pregnancy. Mean daily doses of 
thiopurine and allopurinol were AZA 41 mg [n  =  4], 6MP 31mg 
[n = 9], and allopurinol 108 mg. The median duration of co-therapy 
before successful conception was 12 months, [range 1–72 months]. 
All patients demonstrated a good treatment response with co-ther-
apy based on clinical grounds, as evidenced by improvements in the 
simple clinical colitis score for UC and the Harvey Bradshaw Index 
for CD activity, with disease activity largely in remission or only 
mild at time of conception.
There were 14 live births, as one pregnancy [case 13] resulted 
in twins. One patient became pregnant twice [first pregnancy Case 
5 and second pregnancy Case  12]; both of her pregnancies were 
achieved with in vitro fertilisation. For all pregnancies except one 
[Case  4], drug doses were maintained the same as those before 
conception. Case 4 had been receiving AZA 50 mg and allopurinol 
100 mg but developed hepatotoxicity as evidenced by a rise in ala-
nine aminotransferase [ALT]; this resolved on increasing the allopu-
rinol dose to 200 mg. Co-therapy was well tolerated in pregnancy, 
with only one patient [Case 10] stopping allopurinol at 6 months 
due to nausea. Medications taken during pregnancy are listed in 
Table 1. All patients took folic acid supplementation.
Median age at pregnancy was 31 years, range 21 to 36. There 
were no reported miscarriages or terminations. There was only one 
disease flare during pregnancy [Case 2], which occurred at 30 weeks, 
was mild, and was treated successfully with mesalazine enemas. No 
fetal abnormalities were noted in utero on ultrasound scan examina-
tions except for Case 13, which was a primagravid twin pregnancy 
complicated by pre-eclampsia and twin-to-twin transfusion syn-
drome [TTTS]. There were no spontaneous pre-term deliveries [i.e. < 
37 weeks]. Seven patients gave birth by spontaneous vaginal delivery 
[SVD] and six by caesarean section [C-section] [Cases 2, 3, 7, 8, 
11, and 13]. One patient [Case 7] had a C-section at 36 weeks. She 
had cervical incompetence and insertion of a cervical suture. This 
patient [with UC] had previously suffered a miscarriage of twins at 
24 weeks, which occurred during a severe disease flare, before the 
commencement of co-therapy. She was also taking liposomal cyclo-
sporine throughout her pregnancy. Case 2 required an emergency 
C-section for failure to progress in labour and Case 3 because of a 
previous C-section. Elective C-sections were performed for Cases 8 
and 11. Case 13, who underwent a C-section at 25 weeks for pre-
eclampsia and TTTS, delivered two live babies weighing less than 
400 g. One twin did not survive beyond 13 weeks post delivery due 
to respiratory failure and an intracerebral bleed; the other twin was 
doing well at 16 weeks.
Except for Case 13 there were no low birthweight babies [< 
2.5 kg] and the APGAR scores of all babies were normal at 1 and 
5 min. Subsequent routine neonate checks identified no evidence of 
congenital malformations, other medical abnormalities or infectious 
complications. The median duration of follow-up of babies was 
6 months. There has been no indication of any morbidity such as 
failure to thrive during the follow-up period. Vaccination of neo-
nates has occurred in accordance with standard national protocols 
with no evidence of any infectious complications.
3. Discussion
All 12 IBD patients were treated successfully with thiopurine and 
allopurinol before and during their pregnancies. There were no adverse 
pregnancy-related events or adverse fetal or neonatal outcomes with 
the exception of Case 13, who had pre-eclampsia and TTTS. TTTS 
complicates approximately 10% of monochorionic diamniotic 
pregnancies and is a consequence of intertwin vascular connections 
within the placenta leading to an imbalance of blood flow.12 It is not 
known to be related to maternal drug treatment. Pre-eclampsia affects 
3–5% of pregnancies, is more common in multiple and primiparous 
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pregnancies, and is not thought to be related to thiopurine therapy.13 
Although we did not measure thiopurine metabolite levels, intrau-
terine exposure of the fetus to thiopurine metabolites [6-TGN and 
6-MMP] is not greater with combination therapy compared with thio-
purine monotherapy.9 Allopurinol and its metabolite oxypurinol have 
been shown to cross the placenta following a single dose of maternal 
allopurinol but at levels lower than maternal plasma levels.14
A large prospective case series [n = 31] of maternal use of allopu-
rinol during pregnancy for primary and secondary hyperuricaemia 
was recently published.15 It reported that the rates of congenital mal-
formations and spontaneous miscarriages were in the expected range, 
as were birthweights. However the prematurity rate of 19% was 
high, which the authors ascribed to the serious underlying disease 
comorbidity rather than allopurinol use. One child was born with 
serious congenital malformations, which appeared to be phenotypi-
cally similar to the only case report suggesing a potential teratogenic 
effect of allopurinol.16 However, the case for an association based on 
the two cases is weak. Moreover we suspect there is also likely to be 
a negative publication bias with respect to allopurinol use and suc-
cessful pregnancy outcomes, given the scarcity of allopurinol-related 
pregnancy data over the five decades for which allopurinol has been 
used. On the other hand, use of maternal allopurinol at the time of 
birth could protect the fetus against the effects of hypoxia.14
A limitation of this retrospective case series is the relatively small 
number of patients, so the probability of detecting an uncommon 
congenital malformation is unlikely. Although comprising only 13 
pregnancies, the series is the largest reported to date.
In conclusion, adverse pregnancy-related events attributable to 
combination thiopurine and allopurinol therapy for IBD were not 
detected. Importantly, it is of clinical significance that co-therapy 
was efficacious in maintaining disease remission during pregnancy, 
because disease flares are the main prognosticator for poor preg-
nancy outcomes.
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